OncRef

Clinical Trial: NCT04919369

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Dwight Owen
Information Provided By:Ohio State University Comprehensive Cancer Center
Last Update Posted:2026-07-20

Study Overview

Brief Summary

This phase Ib trial is to find out the best dose and side effects of all-trans retinoic acid (ATRA) and atezolizumab in treating patients with non-small cell lung cancer that has come back (recurrent) or has spread to other places in the body (metastatic). All-trans retinoic acid (ATRA) is made in the body from vitamin A and helps cells to grow and develop. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving all-trans retinoic acid (ATRA) and atezolizumab may help treat patients with non-small cell lung cancer.

Official Title

A Phase Ib Dose De-Escalation Study of All-Trans Retinoic Acid (ATRA) and Atezolizumab in Patients With Advanced Non-Small Cell Lung Cancer

Conditions

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

Intervention / Treatment

  • Biological: Atezolizumab
  • Drug: Tretinoin

Other Study ID Numbers

  • OSU-20171
  • NCI-2021-03310

Start Date (Actual)

2021-10-18

Primary Completion Date (Actual)

2025-09-20

Study Completion Date (Actual)

2026-07-03

Enrollment (Actual)

18

Study Type

Interventional

Phase

Phase 1